article thumbnail

CAFC Says District Court Committed ‘Clear Error’ in Enforcing Disputed Settlement Agreement

IP Watchdog

On appeal, the CAFC held that CNC’s version of the agreement more accurately reflected the understanding between the two parties regarding a settlement over Plasmacam’s claim that CNC infringed U.S. 7,071,441 (‘441 patent), for which Plasmacam has an exclusive license.

article thumbnail

Litigation as a Source of Profit? Non-Practicing Entities and Patent Litigation

IPilogue

Litigation is almost always recommended to be avoided , whether because of the sheer amount of time needed to get a court date, the expensive costs for the client and law firm, or the risks associated with receiving an unfavorable judgement. Michelle Mao is an incoming 2L JD student at Osgoode Hall Law school and an IPilogue Writer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Appealing IPR Decisions – Art. III Standing in the Context of Litigation Settlements and Licenses

JD Supra Law

The Federal Circuit has provided additional guidance about an appellant’s standing to appeal IPR decisions after settling the related litigations and entering into patent license agreements. In its second decision between the parties on this topic, the court has dismissed the appeal for lack of Article III standing in Apple Inc.

article thumbnail

Roblox is Latest Online Platform to Settle NMPA Copyright Claims with Collaborative Music Licensing Agreement

IP Watchdog

On September 27, the National Music Publishers’ Association (NMPA) and online game platform provider Roblox announced that the two parties had settled ongoing copyright litigation in the Central District of California over Roblox’s unauthorized use of copyrighted music on its online gaming platform.

Music 105
article thumbnail

Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation

JD Supra Law

Samsung Bioepis recently reported that it has signed a settlement and license agreement with Johnson & Johnson (“J&J”) in the United States relating to SB17, Samsung Bioepis’s ustekinumab biosimilar to J&J’s STELARA®. If SB17 is approved by the FDA, the license period in the United States will begin on February 22, 2025.

article thumbnail

Court Denies Attempts to Compel Disclosure of Litigation Funding Documents

The IP Law Blog

Kewalramani), the Central District of California denied Defendant Netflix’s attempts to compel Plaintiff GoTV Streaming to provide documents and further information as to the source of the litigation funding that GoTV received in conjunction with the patent litigation.

article thumbnail

Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation

LexBlog IP

The post Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation appeared first on Big Molecule Watch.